BioCryst Pharmaceuticals Inc (BCRX) — Cash Flow Quality Index

Latest as of December 2025: 0.76x

BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Quality Index of 0.76x as of December 2025. Operating cash flow of $276.04 Million is below net income of $362.26 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore BioCryst Pharmaceuticals Inc (BCRX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

0.76x

Operating CF / Net Income

Operating Cash Flow

$276.04 Million

USD

Net Income

$362.26 Million

USD

Data as of

Dec 2025

Most recent filing

BioCryst Pharmaceuticals Inc Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for BioCryst Pharmaceuticals Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see BCRX cash flow metrics.

Annual Cash Flow Quality Index for BioCryst Pharmaceuticals Inc (2025–2025)

Year-by-year earnings quality comparison for BioCryst Pharmaceuticals Inc.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change
2025	1.25x	$329.88 Million	$263.86 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.